Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | PDE2A | O00408 | 10/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25164972 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2GSK3BPDE2ASLC6A3 | |
| SCHEMBL31231913 | 0.79 | CYP3A4 (0.57) | NOS3NOS1NOS2MEN1ALDH1A1 | |
| SCHEMBL12566436 | 0.79 | GSK3B (0.53) | GSK3BPDE2ANOS3NOS1NOS2 | |
| SCHEMBL25409411 | 0.78 | KDM5B (0.38) | SMN1; SMN2GSK3BNOS3NOS1NOS2 | |
| SCHEMBL5935763 | 0.73 | — | — | |
| SCHEMBL24729665 | 0.71 | MAPT (0.50) | NOS3NOS1NOS2KDM5BMEN1 | |
| SCHEMBL24066325 | 0.71 | TSHR (0.38) | SMN1; SMN2GSK3BPDE2ANOS3NOS1 | |
| SCHEMBL13375700 | 0.70 | — | — | |
| SCHEMBL18689667 | 0.70 | — | — | |
| SCHEMBL11937375 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-9809598-B2 | Heterocyclyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| US-8362068-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-4163848-A | Process for the production of 2-alkyl- or cycloalkyl-4-methyl-6-hydroxypyrimidines | CIBA-GEIGY CORPORATION (US) | 1979-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | HAVCR2, CYP3A5, CYP2E1 | SMN1; SMN2 4507/4885GSK3B 1828/4885PDE2A 3846/4885 |
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | RBM17, SF3B1, SF3B5 | SMN1; SMN2 88/4885GSK3B 2913/4885PDE2A 2208/4885 |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | TNKS, TANK, TBKBP1 | SMN1; SMN2 2378/4885GSK3B 140/4885PDE2A 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.